new_0222_0566|DYN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0566|DYN|1|Dyne Therapeutics Inc Total Current Assets (Quarterly) (USD)|Dyne Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Dyne Therapeutics Inc Inventories (Quarterly) (USD)|Dyne Therapeutics Inc Net PP&E (Quarterly) (USD)|Dyne Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Dyne Therapeutics Inc Total Liabilities (Quarterly) (USD)|Dyne Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Dyne Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Dyne Therapeutics Inc Total Deposits (Quarterly) (USD)|Dyne Therapeutics Inc Book Value (Quarterly) (USD)|Dyne Therapeutics Inc Retained Earnings (Quarterly) (USD)|Dyne Therapeutics Inc Treasury Stock (Quarterly) (USD)|Dyne Therapeutics Inc EV to Revenues|Dyne Therapeutics Inc EV to Earnings|Dyne Therapeutics Inc EV to Free Cash Flow|Dyne Therapeutics Inc EV to Assets (Quarterly)|Dyne Therapeutics Inc PS Ratio|Dyne Therapeutics Inc PE Ratio|Dyne Therapeutics Inc Price to Book Value|Dyne Therapeutics Inc PEG Ratio|Dyne Therapeutics Inc Debt to Equity Ratio|Dyne Therapeutics Inc Dividend Yield|Dyne Therapeutics Inc Shareholder Yield (TTM)|Dyne Therapeutics Inc Percent of Shares Outstanding Short|Dyne Therapeutics Inc Total Receivables (Quarterly) (USD)|Dyne Therapeutics Inc Total Payables (Quarterly) (USD)|Dyne Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Dyne Therapeutics Inc Return on Invested Capital|Dyne Therapeutics Inc Quality Ratio Score|Dyne Therapeutics Inc Momentum Score|Dyne Therapeutics Inc Beta (1Y)|Dyne Therapeutics Inc Sustainable Growth Rate (TTM)|Dyne Therapeutics Inc Institutional Investor Ownership Percentage|Dyne Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Dyne Therapeutics Inc Total Employees (Annual)|Dyne Therapeutics Inc EPS Diluted (Quarterly) (USD)|Dyne Therapeutics Inc SG&A Expense (Quarterly) (USD)|Dyne Therapeutics Inc Shares Outstanding|Dyne Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Dyne Therapeutics Inc Ordinary Shares Number (Quarterly)|Dyne Therapeutics Inc Payout Ratio|Dyne Therapeutics Inc Quick Ratio (Quarterly)|Dyne Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Dyne Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Dyne Therapeutics Inc Effective Tax Rate (TTM)|Dyne Therapeutics Inc Return on Equity|Dyne Therapeutics Inc Net Income (TTM) (USD)|Dyne Therapeutics Inc Revenue (TTM) (USD)|Dyne Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Dyne Therapeutics Inc Revenue (Quarterly) (USD)|Dyne Therapeutics Inc Gross Profit (Quarterly) (USD)|Dyne Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Dyne Therapeutics Inc Net Income (Quarterly) (USD)|Dyne Therapeutics Inc Net Interest Income (Quarterly) (USD)|Dyne Therapeutics Inc Price (USD)|Dyne Therapeutics Inc Total Return Price (USD)|Dyne Therapeutics Inc Enterprise Value (USD)|Dyne Therapeutics Inc 30-Day Average Daily Volume|Dyne Therapeutics Inc 1 Year Price Returns (Daily)|Dyne Therapeutics Inc Short Interest|Dyne Therapeutics Inc PE Ratio (Forward)|Dyne Therapeutics Inc PE Ratio (Forward 1y)|Dyne Therapeutics Inc PS Ratio (Forward)|Dyne Therapeutics Inc PS Ratio (Forward 1y)|Dyne Therapeutics Inc Quarterly EPS Estimates (USD)|Dyne Therapeutics Inc Quarterly Revenue Estimates (USD)|Dyne Therapeutics Inc Quarterly EPS Surprise|Dyne Therapeutics Inc Quarterly Revenue Surprise|Dyne Therapeutics Inc Quarterly Actual EPS (USD)|Dyne Therapeutics Inc Quarterly Actual Revenue (USD)|Dyne Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Dyne Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Dyne Therapeutics Inc Price Target (USD)|Dyne Therapeutics Inc Consensus Recommendation|Dyne Therapeutics Inc Price Target Num Estimates|Dyne Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Dyne Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Dyne Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Dyne Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Dyne Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Dyne Therapeutics Inc Land and Improvements (Quarterly) (USD)|Dyne Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Dyne Therapeutics Inc Other Properties (Quarterly) (USD)|Dyne Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0566|DYN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0566|DYN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0566|DYN|5|106.5|106.5||106.5||106.5|106.5|106.5||106.5|106.5||||1.44755244755||||1.44568245125|||1.44568245125||15.25||106.5|106.5|||30.6666666667|30.75||30.5|91.375|79|91.375|91.375|30.8571428571||106.5|||91.375|91.3333333333|||91.4|||||91.375|91.375|91.375|1.44568245125|1.44568245125|1.44568245125|1.44848484848|1.43925233645|15.25|||||91.3333333333|91.3333333333|91.25||91.25|91.25|35.6153846154|46.3|30.8666666667|14.0303030303|30.8666666667|21.0454545455|21.0454545455|91.375|91.375|91.375|||106.5|106.5||
new_0222_0566|DYN|6|6|6||6||6|6|6||6|6||||286||||359|||359||32||6|6|||3|4||14|8|5|8|8|14||6|||8|6|||5|||||8|8|8|359|359|359|330|107|32|||||9|9|4||4|4|13|10|15|33|15|22|22|8|8|8|||6|6||
new_0222_0566|DYN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0566|DYN|201909||||||||||||||||||||||||||||||||||12.8181||-0.458|0.647||||||-0.458|||||||||-5.871|-5.871|0.11||||||||||||||||||||||||2.982|0.103|||||||
new_0222_0566|DYN|201912|14.759|14.632||1.486||2.4|2.358|0.042||-13.393|-19.746|||||||||||||||1.256|27.43|||||||12.8181||-0.4215|1.211|||41.6336|||-0.4215|||||||||-5.403|-5.403|0.067||||||||||||||||||||||||4.259|0.146||||1.705|0.062||
new_0222_0566|DYN|202003||||||||||||||||||||||||||||||||||12.8181||-0.6152|1.764||||||-0.6152|||||||||-7.886|-7.886|-0.033||||||||||||||||||||||||6.089|0.15|0.057||||||
new_0222_0566|DYN|202006|145.081|144.872||1.499||14.29|4.134|10.156||132.481|-36.614|||||||||||||||2.192|0.003|||||||41.6336|36|-0.2157|1.341|41.6336||41.6336|||-0.2157||||-28.142|||||-8.982|-8.982|-0.127||||||||||||||||||||||||7.334|0.158|0.127||||||
new_0222_0566|DYN|202009|379.84|379.606||1.441||14.627|4.678|9.949||366.845|-50.534||||||||2.4769|||||0.1672||1.488|0.005||||||73.6134|45.0042|36|-0.3093|3.841|45.0042||45.0042|||-0.3093|-247.454|||-36.191|||||-13.92|-13.92|-0.13|20.19|20.19|538.9648|233971||75245|||||-0.3892||20.3453||-0.31||||34.25|1.5|4|-2.255|-2.2823|9.679|0.175|0.13|||1.993|0.079|20.68|20.16
new_0222_0566|DYN|202012|349.087|345.314||1.946||10.967|10.967|||342.367|-79.183||||-12.614||||2.7649|||||3.6295||3.44|0.005||||||80.9016|45.0766|47|-0.64|6.502|45.0766||45.0766|||-0.64|1.066|||-59.437|||||-28.649|-28.649|-0.049|21|21|601.2946|294355||1636063|||||-0.3776||-68.3129||-0.6356||||34.25|1.5|4|-2.2934|-2.3413|22.098|0.217|0.081|||2.744|0.078|19.33|18.47
new_0222_0566|DYN|202103|487.068|483.085||2.339||13.45|13.45|||478.26|-104.151||||-5.3166||||1.6612|||||3.4766||5.76|0.006||||||94.45|49.4725|56|-0.5|6.509|51.1583||51.1583|||-0.5|-157.237|||-76.519|||||-24.968|-24.968|0.166|15.53|15.53|311.4034|331364.6||1778584|||||-0.6216||19.5663||-0.5||||34|1.5|4|-2.7059|-3.1997|18.625|0.238||||3.325|0.079|19.68|19.11
new_0222_0566|DYN|202106|461.297|435.589||2.965||14.551|14.551|||452.596|-134.106||||-6.5484||||2.3817|||||3.5755||5.649|0.006||||||90.9327|51.2163|71|-0.58|6.293|51.2323||51.2323|||-0.58||||-97.492|||||-29.955|-29.955|0.21|21.04|21.04|642.3386|285620.7||1831799|||||-0.5475||-5.938||-0.58||||34|1.5|4|-2.3496|-2.9861|23.872|0.249||||3.506|0.079|18.07|16.93
new_0222_0566|DYN|202109|424.655|407.523||39.915||52.762|23.351|29.411||414.116|-176.688||||-3.7633||||2.019|||||4.066||7.088|0.006|||2|0.4065||83.3961|51.3209|88|-0.83|6.256|51.4836||51.4836|||-0.83||||-126.154|||||-42.582|-42.582|0.184|16.24|16.24|428.5707|263999.7333|-19.5641|2093348|||||-0.6567||-26.3953||-0.83||||34.75|1.5|4|-2.4667|-3.1533|36.51|0.26||||40.32|0.079|14.51|14.21
new_0222_0566|DYN|202112|||||||||||||||-1.8014||||1.4795|||||5.4182||||||2|0.1269||84.3746||||||||||||||||||||||11.89|11.89|205.1509|198343.2667|-43.381|2791940|||||-0.9654||||||||34.75|1.5|4|-2.8811|-3.9929||||||||7.42|8.07
new_0222_0566|DYN|202203|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.9533|||||||||||||||||||||
new_0222_0566|DYN|202206|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-0.9833|||||||||||||||||||||
new_0222_0566|DYN|202209|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.0133|||||||||||||||||||||
new_0222_0566|DYN|202212|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||-1.04|||||||||||||||||||||